Comprehensive Library Of Resveratrol News

Subscribe to our newsletter to receive email notifications when new articles are posted.

  • Lack of gut/brain hormone called ”glucagon-like peptide-1 (GLP-1) causes lab animals to overeat. But this is old news and drugs already exist to elevate this hormone but are troublesome. Is Resveratrol a better/safer GLP-1 activator?

    July 24, 2015: by Bill Sardi

    The answer to the above question is “we may never know.”  Big Pharma’s and Modern Medicine’s mantra is that the use of herbal supplements is unproven.  Yes, but will they ever put resveratrol to the test in human studies?  Resveratrol has not been disproven as a GLP-1 activator in humans.  It was shown to activate glucagon-like peptide-1 in an animal study.  [PLoS One June 6, 2011]

    The publicity machines behind the drug companies herald the “discovery” of a stop-eating hormone, glucagon-like peptide-1.

    [Daily Mail UK July 23, 2015] But GLP-1 was first described in the 1980s.  So GLP-1 is not new.  In fact, there are already three GLP-1 drugs on the market.

    GLP-1 is being panned as a “stop eating” hormone.  In the most recently published report, the administration of GLP-1 to lab animals reduced their food intake, especially for fatty foods.

    Secretion of GLP-1 is reduced in diabetics.  Replacement of GLP-1 increases secretion of insulin, the hormone secreted by the pancreas that facilitates the use of sugar for cellular energy.

    The problem with GLP-1 drugs is that they are fraught with side effects, the most concerning is pancreatitis (inflammation of the pancreas) that could lead to pancreatic cancer.  Other side effects of GLP-1 drugs include nausea, diarrhea, constipation, vomiting, low blood sugar (hypoglycemia) and suicidal thoughts.  That latter side effect may be caused by GLP-1’s presence in the brain as well as the digestive tract where it affects the brain’s reward center.  [Diabetes Care Feb 2010]

    Given the financial incentives behind development of synthetic molecules, the pharmaceutical industry was obviously more eager to develop glucagon-like peptide-1 drugs (Byetta, and injectable Saxenda, Victoza and Bydureon.  The injectable form of the drug was developed to extend the duration of its biological activity.

    It makes more sense to employ resveratrol which stimulates the body to make more GLP-1 than to rely upon a rapidly decaying drug.  Also, resveratrol is not accompanied by all the side effects and expense associated with GLP-1 drugs.  Resveratrol is actually a remedy for pancreatitis and an pancreatic cancer preventive.  [Cell Biochemistry Biophysics March 2012; PLoS One 2011]  — ©2015 Bill Sardi, Resveratrol

Leave a Reply

In order to submit your comment please complete the calculation below:

Time limit is exhausted. Please reload CAPTCHA.